Pandemic Preparedness Infrastructure Gaps and WHO Reform Implementation: Strategic Readiness Assessment for Next-Generation Biosecurity Threats

Executive Summary

Two major developments now define the next era of global health governance: the 2024 amendments to the International Health Regulations (IHR) and the 2025 WHO Pandemic Agreement. Both instruments arrive at a moment of acute institutional stress. The United States formally exited the WHO on January 22, 2026, following the required one-year notice period triggered by President Trump's Executive Order 14155. That exit, combined with cascading budget reductions across global health security programs, has imposed structural damage on the preparedness architecture that new treaty instruments were designed to strengthen. Global pandemic preparedness is becoming "increasingly fragile at a time of growing biosecurity and geopolitical risk," according to the International Pandemic Preparedness Secretariat. The live Bundibugyo Ebola outbreak, declared a PHEIC in May 2026 and now spanning the DRC and Uganda, is the first real-world test of the reformed architecture -- and the picture is mixed. Decision-makers have a narrow window in 2026 to shore up the system before the reform momentum dissipates.

The Structural Fault Lines In Preparedness Infrastructure

The global pandemic preparedness system rests on three load-bearing pillars: disease surveillance networks capable of early detection, countermeasure development pipelines that can respond within operationally meaningful windows, and governance frameworks that can coordinate international response across sovereign boundaries. All three show stress fractures that the 2025 treaty architecture only partially addresses.

On surveillance, the IHR amendments adopted in 2024 strengthen reporting obligations and introduce new provisions on genomic sequencing data-sharing. In practice, however, surveillance capability is unevenly distributed. The IPPS report notes that a series of outbreaks in 2025 -- including mpox, H5N1, Ebola, Marburg, Rift Valley Fever, Chikungunya, and measles -- demonstrated persistent weaknesses in early detection, coordination, and access. The Bundibugyo Ebola outbreak reinforces this directly: MSF reports that the first cases may have started well before April 2026 but were not reported due to a lack of surveillance and alerts to authorities. Undetected weeks or months of community transmission represent exactly the scenario surveillance investments are meant to prevent.

On countermeasures, the Pandemic Fund's growing portfolio addresses financing gaps for lower-income countries. The broader structural problem -- identified by the IPPS Scorecard -- is pipeline concentration and funder dependency. The 100DM Scorecard highlights heavy reliance on a small number of funders, which means any single donor's policy shift creates system-wide fragility. The Bundibugyo situation illustrates the countermeasure gap most starkly: unlike Ebola-Zaire strains, there are currently no approved Bundibugyo virus-specific therapeutics or vaccines. This gap was known before 2026. The interplay between sparse R&D investment in lower-priority pathogens and outbreak-driven demand creates a recurring cycle that neither the Pandemic Agreement's PABS framework nor the 100DM Therapeutics Coalition has yet broken.

On governance, the 2025 WHO Pandemic Agreement provides a more binding legal architecture than existed under the pre-2024 IHR. A published peer-reviewed analysis in the International Journal of Environmental Research and Public Health identifies persistent gaps in governance (limited enforceability, fragmented coordination), equity (inequitable access to medical countermeasures), capacity (technology transfer and financing), and accountability as the core challenges -- and assesses that the Agreement addresses these challenges unevenly. Enforceability remains the weakest dimension: the Agreement creates obligations but limited verification or sanction mechanisms. Even if the PABS annex is successfully negotiated, the Agreement's effectiveness will be severely tested by geopolitical fractures. The United States, citing concerns over binding technology transfer provisions, sovereignty, and pharmaceutical innovation incentives, did not participate, and 11 key countries abstained.

The U.S. Withdrawal: Tactical Withdrawal Or Strategic Reorientation?

The U.S. exit from WHO creates an asymmetric shock. For the WHO, the loss is primarily financial and epistemic -- the organization loses its largest single contributor and a dense network of embedded scientific expertise. For the United States, the costs are primarily operational and informational, manifest over a longer time horizon.

The dissolution of USAID and integration of remaining global health activities into the State Department's Bureau of Global Health Security and Diplomacy raises questions about operational continuity, given that GHSD has historically focused on coordination and diplomatic roles rather than the in-country implementation roles that USAID and CDC led on. The administration's stated alternative -- bilateral agreements and direct CDC country presence -- faces a structural limitation that Georgetown's Dr. Kavanagh identified precisely: the WHO's value is precisely its ability to coordinate with countries that are not U.S. allies. Health analysts caution that withdrawal may reduce U.S. access to shared disease monitoring systems and diminish its influence in shaping future pandemic response frameworks.

The broader geopolitical and security implications are mutually reinforcing with domestic capacity reductions. Pandemics weaken national security by disrupting critical infrastructure and diminishing workforce capacity. A United States that detects outbreaks later, responds more slowly, and exercises less norm-setting influence over international health governance is a United States carrying greater biosecurity exposure -- not less. These security and economic dimensions of the withdrawal decision require attention beyond their immediate foreign policy framing.

This pressure translates directly into an opportunity for other actors. When the U.S. served notice of withdrawal during Trump's first term, other countries stepped into the void to increase funding for the organization. Whether European Union member states, the United Kingdom, Japan, and China can collectively substitute for U.S. financial and technical capacity -- without reproducing the coordination fragmentation that undermined COVID-19 response -- is a key open question for the 2026-2027 period.

The Pabs Annex: Where The Treaty Lives Or Dies

The 2025 WHO Pandemic Agreement is architecturally complete but operationally suspended. Its core equity mechanism -- the Pathogen Access and Benefit Sharing system -- remains unresolved. Understanding what is at stake in the PABS negotiation clarifies why it is so contested.

The PABS system aims to achieve equity by addressing two main areas: ensuring scientists and public health researchers have access to samples and genetic sequencing data, and securing diagnostics, vaccines, and therapeutics for distribution to countries during a pandemic. This mechanism sits at the nexus of intellectual property rights, national sovereignty over biological materials, and pharmaceutical market incentives -- all domains where interests between high-income and low-income country blocs structurally diverge.

WHO member state negotiations face barriers, particularly on intellectual property rights, equitable vaccine distribution, and pathogen sample sharing, with tensions between high-income countries and LMICs over resource allocation and benefit sharing. The Council on Foreign Relations' senior fellow Stephanie Psaki, writing in Think Global Health in June 2026, framed the current Ebola outbreak as a direct test of whether the new architecture can deliver: the Bundibugyo response is operating without the U.S. contribution that historically anchored outbreak financing and technical response, while the PABS mechanism that was supposed to formalize benefit-sharing for exactly this kind of event remains unsigned.

The IPPS, CEPI, FIND, and DNDi in a joint statement in April 2026 identified that enabling the policy environment includes the finalization of the Pandemic Agreement through consensus on a practical, workable, and equitable system for pathogen access and benefit sharing. Without this, the broader ecosystem of preparedness investments -- R&D pipeline, regulatory harmonization, manufacturing network readiness -- lacks the legal framework to coordinate deployment at scale.

Where The 100 Days Mission Falls Short

The 100 Days Mission represents perhaps the most operationally concrete benchmark in the preparedness architecture. Its premise -- that safe, effective diagnostics, therapeutics, and vaccines can be available within 100 days of a pandemic threat being identified -- sets a against which current capability can be measured.

The IPPS Fifth Implementation Report is direct in its assessment: the 100-day target is not yet achievable in many areas, with significant gaps persisting across diagnostics, therapeutics, vaccines, and the systems required to deliver them rapidly and equitably. The 2026 Ebola Bundibugyo outbreak makes this concrete. As of mid-June 2026, the outbreak had been declared a PHEIC, cases had spread across international borders into Uganda, and emergency teams were still closing surveillance and contact-tracing gaps that should have been addressed by preparedness infrastructure built in the post-COVID period.

The IPPS identifies four priority action areas for 2026: operationalizing the Therapeutics Development Coalition to address persistent gaps in antiviral R&D; enhancing coordination across the diagnostics ecosystem and implementing recommendations from the Global Diagnostics Gap Assessment; sustaining vaccine investment; and establishing a long-term path for the 100DM Scorecard beyond IPPS's 2027 mandate. The broader systemic implications include the risk that the institutional architecture built to sustain preparedness monitoring will itself lapse if mandate and funding gaps are not addressed.

Securitization Theory Analysis

Securitizing Actor: Multiple actors are simultaneously securitizing pandemic preparedness, but through conflicting frames. The WHO and multilateral health institutions frame pandemic risk as a collective security threat requiring cooperative governance. The U.S. administration frames pandemic preparedness as a sovereignty and accountability question requiring national control.

Referent Object: The primary referent objects are the population's physical security and economic stability, invoked by both framing camps. The WHO frame emphasizes the global population. The U.S. frame emphasizes the American population specifically.

Existential Threat Construction: WHO Director-General Tedros has framed the Bundibugyo outbreak as evidence of a failing system, warning publicly that response teams are "playing catch-up." The IPPS describes preparedness as "increasingly fragile." The U.S. administration frames the WHO itself as a threat to American sovereignty and innovation -- a security framing applied to the institution rather than to pathogens.

Target Audience: The WHO and IPPS are seeking consent from member state governments and the multilateral donor community. The U.S. administration is seeking domestic political consent for its unilateral posture.

Extraordinary Measures: The WHO's May 2026 PHEIC declaration for Bundibugyo Ebola constitutes an extraordinary measure under IHR Article 12, authorizing temporary recommendations to all states. The U.S. withdrawal itself constitutes an extraordinary departure from 75 years of multilateral health engagement.

Classification: SECURITIZED

The issue has been accepted as existential by major actors, and extraordinary governance measures -- a new binding treaty, a PHEIC declaration, a complete WHO exit by the world's former largest funder -- are operational. The contest is not over whether pandemic preparedness is a security issue, but over which architecture should govern it.

Process Tracing Analysis

Cause and Outcome: The cause being traced is the structural fragmentation of global health governance (withdrawal of key member states, funding reductions, PABS stalemate) and the outcome is degraded pandemic preparedness capacity at the moment of active outbreak.

Causal Mechanism Chain:

1. The U.S. initiates WHO withdrawal in January 2025, begins defunding and recalling personnel.
2. Global health security program budgets are cut; USAID dissolved; CDC field staff reduced.
3. The WHO Pandemic Agreement is adopted in May 2025 but left structurally incomplete pending PABS annex.
4. Funding gaps compound as humanitarian financing falls below 2016 levels per WHO's 2026 emergency appeal.
5. The Bundibugyo Ebola outbreak begins in April 2026 in Ituri Province, undetected for weeks due to surveillance gaps.
6. WHO declares PHEIC on May 17, 2026, with response teams behind the outbreak curve and no approved countermeasures for the Bundibugyo strain.

Evidence Assessment:

• The surveillance failure (weeks of undetected transmission) is a smoking gun linking underfunded early warning systems to outbreak acceleration.
• The absence of Bundibugyo-specific countermeasures is a hoop test that the preparedness system fails: without this capability, the 100DM is inoperable for this pathogen class regardless of governance architecture.
• The USAID staffing collapse (50 to 6 outbreak response staff) is doubly decisive: necessary for the claim that U.S. operational capacity degraded, and its absence would remove a central pillar of the argument.

CAUSAL_MECHANISM_STRENGTH: MODERATE

The mechanism is plausible and supported by multiple corroborating evidence streams. It does not yet rise to STRONG because alternative explanations -- the DRC's persistent governance challenges, regional insecurity in Ituri Province, the inherent difficulty of Bundibugyo containment -- provide competing causal pathways that cannot be fully ruled out with current information.

Counterarguments

1. The preparedness glass is half-full, not half-empty: The WHO's 2026 emergency assessment notes genuine improvements since COVID-19, including new IHR amendments, a $1.2 billion Pandemic Fund supporting 98 countries, and AI-powered surveillance in over 110 countries tracking emerging threats faster. Africa CDC's growing mandate, regional manufacturing initiatives, and Rwanda's integration of the 100DM framework into national planning represent real advances. An assessment that centers exclusively on governance fragmentation risks underweighting the distributed resilience that these regional capacities represent. The Council on Foreign Relations and others note that the IPPS itself identifies African regulatory maturity as growing. A more distributed preparedness architecture may be more resilient to single-donor shocks than the pre-2020 system was.

2. The U.S. withdrawal may catalyze reforms the WHO resisted under U.S. influence: A recurring critique of the pre-2026 WHO -- documented in academic literature including the Journal of Health Politics, Policy and Law -- is that U.S. dominance shaped WHO priorities toward high-income-country preferences, potentially at the expense of equitable countermeasure access. The COVID-19 vaccination gap, with coverage reaching nearly 80% in high-income nations while only 30% in low-income countries, did not merely prolong the pandemic but inflicted avoidable deaths and a global economic shockwave. The U.S. exit, while operationally damaging, may create space for WHO governance reforms and PABS negotiations that U.S. opposition previously blocked. Whether this theoretical benefit materializes depends on whether other high-income funders fill the financial gap.

3. The Bundibugyo outbreak may be testing a baseline that existed before any 2024-2025 reforms could take effect: Implementation timelines for treaty obligations typically run three to five years after entry into force. The 2024 IHR amendments and 2025 Pandemic Agreement cannot reasonably be expected to have materially changed surveillance capacity in Ituri Province by May 2026. Using the Bundibugyo response as evidence that the new architecture is failing conflates the absence of results with failure -- the architecture may simply not yet be operational. The more diagnostic test of the reform agenda will come in 2028-2030, when implementation timelines have matured.

Indicators To Watch

Decision Relevance

Scenario A (~55%): Reform architecture advances incrementally, Ebola contained, PABS annex adopted in modified form. The 79th World Health Assembly adopts a provisional PABS arrangement in mid-2026 that preserves the Agreement's entry-into-force pathway. The Bundibugyo outbreak is contained within 3-4 months, though with higher mortality than optimal. European donors partially compensate for the U.S. funding gap. The 100DM target remains aspirational but the monitoring architecture survives. Recommended: For multinationals with supply chain exposure in sub-Saharan Africa, maintain enhanced outbreak monitoring through Africa CDC feeds rather than relying on legacy U.S. government early warning channels; update business continuity plans accordingly. For pharmaceutical companies, accelerate engagement with the Therapeutics Development Coalition to position for PABS-linked benefit obligations before ratification.

Scenario B (~35%): PABS annex fails, preparedness fragmentation deepens, and the next zoonotic spillover encounters a degraded response architecture. Negotiations collapse on benefit-sharing modalities, leaving the Pandemic Agreement in legal limbo. U.S. bilateral alternatives prove insufficient to replace multilateral surveillance in non-allied states. The Pandemic Fund faces a funding plateau as donor enthusiasm wanes. The IPPS mandate expires in 2027 without a credible successor. Recommended: Corporate risk managers should treat this as the planning scenario for supply chain and workforce continuity investments. The window to advocate for national governments to fill specific WHO funding gaps -- laboratory network financing, GOARN deployment capacity -- is now. Organizations dependent on stable low-income-country operating environments should develop explicit outbreak-disruption scenarios for 2027-2028.

Scenario C (~10%): U.S. re-engages with WHO under changed terms, restoring the system's funding floor. A domestic political shift or a sufficiently severe outbreak event triggers a recalibration of U.S. global health engagement -- either formal re-accession or a structured financial relationship outside WHO membership. This would substantially restore the preparedness architecture's financial base and surveillance network integrity. Recommended: Do not position for this scenario in 2026 planning horizons; treat as a low-probability upside that would invalidate several of the risk investments recommended under Scenarios A and B. Monitor the September 2026 UN High-Level Meeting on PPPR for any signal of U.S. re-engagement posture.

Expert Integration

The academic literature -- including the peer-reviewed scoping review published in IJERPH in November 2025, the PMC analysis of the Agreement's implementation, and the NEJM commentary on the U.S. withdrawal -- converges on the assessment that the new treaty architecture is necessary but insufficient without U.S. participation and without PABS resolution. The International Pandemic Preparedness Secretariat, CEPI, FIND, and DNDi represent the operational expert consensus in their April 2026 joint statement.

Expert Disagreement Areas

• Whether U.S. bilateral alternatives are operationally viable: The HHS position (bilateral arrangements are sufficient) conflicts with the Georgetown Center for Global Health Policy analysis that multilateral coordination with non-allied states cannot be replicated bilaterally.
• Whether the Pandemic Agreement's enforceability provisions are adequate: Some academic commentators argue the Agreement's governance architecture represents meaningful progress over the pre-2024 IHR; others in the scoping review literature document that enforceability gaps remain the central unresolved challenge.
• Timeline for preparedness improvement: IPPS frames 2026 as a decisive year requiring immediate action; others argue that reform timelines should be measured in implementation cycles, not calendar years, and that the 2026 Ebola test is premature.

Systematic-Expert Alignment

Alignment: MIXED. This analysis aligns with expert consensus on the structural fragility of the system and the centrality of the PABS stalemate. It diverges slightly from the most pessimistic readings by treating the Pandemic Fund's scale-up and Africa CDC's growing capacity as meaningful buffers that reduce -- but do not eliminate -- the vulnerability created by U.S. withdrawal. The weight given to the Bundibugyo outbreak as a diagnostic test is consistent with the IPPS and Council on Foreign Relations framing, though the counterargument that the outbreak predates reform implementation is taken seriously.

Analytical Limitations

• The full scope of U.S. CDC field presence reduction is not publicly quantified beyond the USAID staffing collapse. The current operational footprint of CDC global health security programs is not verifiable through open sources, meaning the U.S. bilateral alternative's actual capacity cannot be precisely assessed.
• The PABS negotiation is conducted under partial opacity; public reporting captures stated positions but not the specific technical proposals on the table. If negotiating parties are closer to agreement than public signals suggest, the urgency of the annex bottleneck may be overstated.
• Bundibugyo Ebola case counts and mortality figures as of June 24, 2026, remain preliminary; WHO notes that the DRC Ministry of Health's surveillance system is operating under humanitarian access constraints in Ituri Province, meaning confirmed cases moderate-to-high confidence understate actual transmission.
• This assessment does not model the counterfactual -- what the Bundibugyo response would look like under a fully resourced, pre-2025 preparedness architecture. Without that counterfactual, the causal attribution between governance fragmentation and response failure is plausible but not definitively established.
• Financing data for the Pandemic Fund's actual disbursements versus portfolio commitments are reported with a lag, meaning the effective resources reaching country-level programs may differ from headline portfolio figures.